Eva-Maria Heurich
Family Medicine · Orlando, FLNPI 1811243611
Payments from drug & device makers
Across 2,386 payments — averaging $4717.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4.9M
- AbbVie$1.3M
- Bavarian Nordic A/s$1M
- Sanofi Pasteur Inc.$662K
- Eli Lilly$559K
- Incyte Corporation$439K
- plus $2.4M from 23 others
Across 28 payments — averaging $7388.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Orexo US, Inc.$153K
- Valneva Austria GmbH$28K
- Pfizer$15K
- Eli Lilly$10K
What the payments were for
- Travel & lodging$85554%
- Food & beverage$72946%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 1,012 | $4,899,980 |
| AbbVie(2 entities) | 182 | $1,285,638 |
| Bavarian Nordic A/s | 40 | $1,024,565 |
| Sanofi Pasteur Inc. | 15 | $661,507 |
| Eli Lilly | 46 | $558,660 |
| Incyte Corporation | 544 | $438,509 |
| Novartis | 8 | $404,244 |
| Intercept Pharmaceuticals, Inc. | 124 | $369,767 |
| Vertex | 6 | $345,551 |
| Valneva Austria GmbH | 3 | $267,334 |
| Sage Therapeutics, LLC | 16 | $224,716 |
| Pfizer | 81 | $177,890 |
| Teva Pharmaceuticals USA, Inc. | 33 | $127,459 |
| Eisai Inc. | 37 | $82,083 |
| Avanir Pharmaceuticals, Inc. | 34 | $74,638 |
| Hikma Pharmaceuticals USA | 9 | $55,484 |
| AstraZeneca | 4 | $54,533 |
| H. Lundbeck A S | 12 | $52,350 |
| Intercept Pharma Europe Ltd. | 13 | $51,856 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $39,161 |
| Chiesi USA, Inc. | 3 | $16,352 |
| Alnylam Pharmaceuticals Inc. | 18 | $16,103 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14,190 |
| Novo Nordisk AS | 132 | $9,262 |
| Sanofi US Services Inc. | 3 | $2,417 |
| Janssen Research & Development, LLC | 2 | $650 |
| Galderma Laboratories, L.p. | 1 | $137 |
| Amgen | 1 | $85 |
| E.r. Squibb & Sons, L.L.C. | 1 | $61 |
How this compares
$11,255,180 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $9,821 |
| XareltoRivaroxaban | 12 | $6,430 |
| FarxigaDapagliflozin Propanediol | 12 | $5,450 |
| Metformin Hcl | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $54,533 | $5,45012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Orlando
- Humberto CruzOrlando$10.7M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.